<!DOCTYPE html><html><head><meta charset='utf-8'><meta name='viewport' content='width=device-width, initial-scale=1'><script async src='https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8422244967817077' crossorigin=anonymous'></script><link rel='stylesheet' href='/class.css'><script src='/script.js'></script></head><body><div class='topnav'></div><div class='list'><Br/><a href='4539.html'>Golf at Augusta Na</a><Br/><a href='4540.html'><?php
namespace Br</a><Br/><a href='4541.html'>Q:

CakePHP: The v</a><Br/><a href='4542.html'>/*

  This file is</a><Br/><a href='4543.html'>This is an archive</a><Br/><a href='4544.html'>Erythropoietin tre</a><Br/><a href='4545.html'>Q:

Getting this e</a><Br/><a href='4546.html'>The role of the en</a><Br/><a href='4547.html'>Q:

Does .NET 4.0 </a><Br/><a href='4548.html'>

Dedicated to the</a></div><div class='stats'><div class='logodiv'><a href='/'><img class='logoimg' src='/img/elephant.svg' /></a></div> <Br/><a href='4537.html'>OAKLAND, Calif. â€“ </a><Br/><a href='4536.html'>Sidney Mier

Sidne</a><Br/><a href='4535.html'>This application r</a><Br/><a href='4534.html'>Fetal echocardiogr</a><Br/><a href='4533.html'>//
//  YJDemo1View</a><Br/><a href='4532.html'>Sri Lanka: Massacr</a><Br/><a href='4531.html'>#ifndef ROUTER_H
#</a><Br/><a href='4530.html'>1. Technical Field</a><Br/><a href='4529.html'>1. Field of the In</a><Br/><a href='4528.html'>Synthesis, propert</a></div><div class='nav'><a href='4537.html'> << </a>&nbsp;&nbsp;&nbsp;&nbsp;<a href='4539.html'> >> </a></div><div class='article'>In vitro and in vivo evaluation of the antiviral activity of 1-hexadecyloxycarbonyl-2-(6-methyl-9H-purin-9-ylamino)ethane as an antiherpes agent.
In the search for antiherpetic agents, a potent antiherpetic agent named 1-hexadecyloxycarbonyl-2-(6-methyl-9H-purin-9-ylamino)ethane (compound II) was synthesized from a mixture of (1R,2R)-(+)-glycidyl 3-nitrobenzyl ester and 7-(2,6-diamino-4-azatetralin)-1H-purine through six steps, and its activity against herpes simplex virus (HSV) type 1 was studied. As a result, compound II was found to be extremely potent in inhibiting the replication of HSV with an EC50 value of 9.6 microM. As a potent antiherpetic agent, compound II exhibited a dose-dependent reduction in HSV plaque formation in three different types of HSV-infected monolayers. In addition, compound II was shown to be a potent inhibitor of HSV replication in Vero cells and against a systemic HSV infection in mice. No signs of toxicity were seen in compound II-treated mice. It is therefore considered that compound II can be developed as a new potent antiherpetic agent.</div></body></html><!-- 2022-07-17 11:29:39 